Guidelines for the diagnosis and management of aplastic anaemia :: British Committee for Standards in Haematology

GUIDELINE TITLE
British Committee for Standards in Haematology
Guidelines for the diagnosis and management of aplastic anaemia.

BIBLIOGRAPHIC SOURCE(S)
Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA, British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009 Oct;147(1):43-70. [175 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

February 18, 2010 - Exjade (deferasirox): Novartis Oncology and the U.S. Food and Drug Administration (FDA) notified healthcare professionals about recent changes in the Prescribing Information (PI) for Exjade, indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. New language was added to the Contraindications, Warnings and Precautions, and Drug Interactions sections of the PI, including a Boxed Warning that the product may cause renal impairment, including failure; hepatic impairment, including failure; and gastrointestinal hemorrhage.

open here to see the full-text:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=15515&nbr=&string=